Publicaciones en colaboración con investigadores/as de Hospital Clínico Universitario Lozano Blesa (18)

2024

  1. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management

    United European Gastroenterology Journal, Vol. 12, Núm. 1, pp. 122-138

2023

  1. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)

    Gut, Vol. 72, Núm. 6, pp. 1054-1072

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: A Spanish Multicentre Study

    Journal of Clinical Medicine, Vol. 11, Núm. 17

  3. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  4. V Spanish Consensus Conference on Helicobacter pylori infection treatment

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 392-417

2021

  1. Clinical practice guidelines. v spanish consensus conference on helicobacter pylori infection treatment

    Revista Espanola de Enfermedades Digestivas, Vol. 113, Núm. 10, pp. 740-763

  2. European registry on helicobacter pylori management: Effectiveness of first and second-line treatment in Spain

    Antibiotics, Vol. 10, Núm. 1, pp. 1-15

  3. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

  4. The role of statins on helicobacter pylori eradication: Results from the european registry on the management of h. pylori (hp-eureg)

    Antibiotics, Vol. 10, Núm. 8

2020

  1. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

  2. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)

    Helicobacter, Vol. 25, Núm. 3

2019

  1. Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results from the ENEIDA Registry

    Inflammatory Bowel Diseases, Vol. 25, Núm. 11, pp. 1862-1870

  2. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

2018

  1. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study

    American Journal of Gastroenterology, Vol. 113, Núm. 3, pp. 396-403

2017

  1. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry

    American Journal of Gastroenterology, Vol. 112, Núm. 7, pp. 1135-1143

2016

  1. Incidence, clinical characteristics, and management of psoriasis induced by Anti-TNF therapy in patients with inflammatory bowel disease: A nationwide cohort study

    Inflammatory Bowel Diseases, Vol. 22, Núm. 4, pp. 894-901

2014

  1. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment

    Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293